From Our Partners
Saturday, June 25, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Featured News

NIAID Funds Research on Combination Vaccine Adjuvants

by Global Biodefense Staff
April 4, 2016
West Nile Virus Vaccine

West Nile Virus VaccineThe National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded six grants totaling $3.1 million to researchers exploring the molecular mechanisms behind combination vaccine adjuvants.

Currently, only a limited number of adjuvants are used as vaccine components in the United States. Many current vaccines, or those in development, induce a suboptimal immune response and require large antigen doses, multiple immunizations, or periodic boosting to provide long-term protection. The use of adjuvants in vaccines can enhance vaccine efficacy, promote dose sparing, and may contribute to more rapid and durable immune protection against pathogens.

There is already some evidence that the simultaneous stimulation of various immune targets by combination adjuvants could produce a more effective and longer lasting immune response. Some highly effective vaccines stimulate multiple immune pathways. For example, the attenuated yellow fever vaccine YF-17D is known to produce a high quality immune response (> 98% protection), which lasts for at least 10 years, and up to 35 years, after a single vaccination.

It has been demonstrated that the YF-17D vaccine stimulates innate signaling pathways for Toll like receptors (TLRs) 2, 7, 8 and 9 in dendritic cells, which in turn activate multiple innate and adaptive immune components. The activation of numerous arms of the immune response offers a compelling explanation for the strong and durable protection against infection that is induced by this vaccine.

The development of effective adjuvants is a high-priority research area for NIAID, which has invested significantly in the discovery and development of new adjuvants since 2003.

Grants awarded under this NIAID-led Molecular Mechanisms of Combination Adjuvants research program funds projects designed to shed light on how adjuvants work in combination. These adjuvants may be either in current clinical use or in development. Investigators will study which adjuvants work best together and why, how combinations of adjuvants interact with the immune system, and how synergies between adjuvants can be optimized.

The following institutions received the new grants:

  • Children’s Hospital Corporation, Boston, Massachusetts. Ofer Levy, M.D., Ph.D.
  • Tulane University, New Orleans, Louisiana. James B. McLachlan, Ph.D.
  • Georgia Institute of Technology, Atlanta, Georgia. Krishnendu Roy, Ph.D.
  • University of Wisconsin, Madison. Marulasiddappa Suresh, D.V.M, Ph.D.
  • University of California, Irvine. Aaron Palmer Esser-Kahn, Ph.D.
  • Jackson Laboratory, Farmington, Connecticut. Jacques Banchereau, Ph.D.

Studies by these investigators are expected to help determine optimal combinations of adjuvants capable of triggering long-term protective immune responses to prevent or ameliorate infectious disease.

From Our Partners
Tags: AwardsVaccinesYellow Fever

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC